Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	116.88	120.24	149.24	108.62	59.29
Revenue Growth (YoY)	-2.79%	-19.43%	37.39%	83.21%	33.20%
Cost of Revenue	7.11	1.75	1.08	0.9	0.91
Gross Profit	109.77	118.49	148.15	107.73	58.38
Selling, General & Admin	105.74	112.45	91.89	76.6	74.59
Research & Development	24.52	60.27	65.24	60.1	52.89
Other Operating Expenses	0	1.32	3.52	0	0
Operating Expenses	130.26	174.04	160.65	136.7	127.47
Operating Income	-20.49	-55.55	-12.5	-28.97	-69.09
Interest Expense / Income	6.87	3.71	4.86	1.35	0.34
Other Expense / Income	-2.27	-0.68	-0.05	-0.58	-2.53
Pretax Income	-25.09	-58.57	-17.31	-29.74	-66.89
Income Tax	0	0	0.61	0	0
Net Income	-25.09	-58.57	-17.91	-29.74	-66.89
Shares Outstanding (Basic)	17	17	17	17	17
Shares Outstanding (Diluted)	17	17	17	17	17
Shares Change	0.93%	1.12%	1.03%	0.81%	4.28%
EPS (Basic)	-1.40	-3.40	-1.10	-1.80	-4.00
EPS (Diluted)	-1.40	-3.40	-1.10	-1.80	-4.00
Free Cash Flow	-5.48	-73.32	5.25	-53.45	-42.97
Free Cash Flow Per Share	-0.32	-4.25	0.31	-3.17	-2.57
Gross Margin	93.92%	98.55%	99.27%	99.18%	98.47%
Operating Margin	-17.53%	-46.20%	-8.37%	-26.67%	-116.53%
Profit Margin	-21.47%	-48.71%	-12.00%	-27.38%	-112.83%
Free Cash Flow Margin	-4.69%	-60.97%	3.52%	-49.21%	-72.47%
EBITDA	-16.98	-53.87	-11.29	-27.69	-65.88
EBITDA Margin	-14.53%	-44.80%	-7.56%	-25.49%	-111.11%
Depreciation & Amortization	1.24	1	1.16	0.71	0.68
EBIT	-18.22	-54.87	-12.45	-28.39	-66.56
EBIT Margin	-15.59%	-45.63%	-8.34%	-26.14%	-112.26%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).